ASCO 2023: AstraZeneca’s PD-1/TIGIT shows promise in checkpoint-exposed NSCLC

[cafead]

via At the American Society of Clinical Oncology (ASCO) Annual Meeting, 2-6 June 2023, initial findings from the Phase I/II ARTEMIDE-01 study investigating rilvegostomig were presented. Parts A and B of the study enrolled advanced or metastatic NSCLC patients with PD-L1–positive disease, who had progressed on at least one prior ICI therapy.

article source